EE | GR | IE | IT | JP | MT | RO | SK | SE | UK | US | N = 11 (100%) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Reported by countries as specific vaccine priority group | ||||||||||||
Long term care facility residentsA | X | 1 (9%) | ||||||||||
Individuals living in "closed communities" (e.g. nursing homes)A | . | X1 | . | . | . | . | . | . | . | 1 (9%) | ||
Individuals in crowding area (e.g. schools) | . | X1 | . | . | . | . | . | . | . | . | . | 1 (9%) |
Staff of workplaces where many people gather (e.g. banks, shops) | . | . | . | . | . | . | . | X | . | . | . | 1 (9%) |
"Selected age groups, depending on national and/or WHO advice"B | . | . | X | . | X | . | . | . | X | . | 3 (27%) | |
Selected industries (e.g. pharmaceuticals)C | . | . | X | . | . | . | . | . | X | . | 2 (18%) | |
(Sub) groups not clearly categorized as belonging to main groups | ||||||||||||
Pandemic vaccine manufacturersD | . | . | . | X2 | . | . | X4 | . | . | . | X5 | 3 (27%) |
Household contacts of immunocompromised personsE | . | . | . | . | . | . | . | X | . | . | X | 2 (18%) |
Household contacts of high-risk patients | X | . | . | . | . | . | . | . | X | . | . | 2 (18%) |
Household contacts of children | . | . | . | . | . | . | . | . | . | . | X | 1 (9%) |
Seniors | X3 | 1 (9%) |